ISRCTN81133184已完成2 期
The addition of Rituximab to Fludarabine and Cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma
niversity College London (UK)0 个研究点目标入组 151 人开始时间: 2003年9月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 151
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age 18 years or older
- •2. Proven mantle cell lymphoma
- •3. Previously untreated disease at any stage requiring therapy
- •4. No previous chemotherapy
- •5. Life expectancy of at least 3 months
- •6. Signed and dated informed consent
排除标准
- •1. Known serological positivity for hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
- •2. Pregnant or breast feeding
- •3. Concomitant uncontrolled serious medical conditions
- •4. Severe renal or hepatic impairment not related to lymphoma
- •5. Known hypersensitivity to murine proteins
- •6. Previous malignancy in the last 5 years (except non-melanomatous skin tumours and carcinoma in situ of the cervix)
- •7. Psychological illness or condition that prevents adequate trial compliance
研究者
相似试验
进行中（未招募）
不适用
Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evaluation of safety and efficacy - RevliRitntreated chronic lymphocytic leukaemia (B-CLL)MedDRA version: 9.1Level: LLTClassification code 10003946Term: B-Lymphocytic, CLL (Kiel Classification)EUCTR2008-001430-27-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
进行中（未招募）
不适用
Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL)EUCTR2011-004912-43-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
进行中（未招募）
不适用
Rituximab-Treatment in Addition to Leflunomide in Patients with active rheumatoid arthritisEUCTR2009-015950-39-DEJohann Wolfgang Goethe-Universität Frankfurt/M.
已完成
1 期
Phase 1 study of fludarabine combined with rituximab followed by Zevalin for patients with relapsed or refractory indolent B cell lymphomaIndolent B cell lymphomaJPRN-UMIN000003867Tohoku Hematology Form12
进行中（未招募）
不适用
First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamiento de primera línea con rituximab combinado con fluradabina, ciclofosfamida y Mitoxantrone (R-FCM) y mantenimiento con rituximab de pacientes con leucemia linfática crónica (LLC) - R-FCM in CPatients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treatedEUCTR2005-001569-33-ESDept. Hematology, Hospital Clinic60